Search

Displaying results 2991 - 3000 of 10000 in total
  1. Drug

    Hydrocodone

    go.drugbank.com/drugs/DB00956
    ApprovedIllicitInvestigational

    Hydrocodone is a synthetic opioid derivative of codeine.[T116] It is commonly used in combination with [acetaminophen] to control moderate to severe pain. … Historically, hydrocodone has been used as a cough suppressant although this has largely been replaced by [dextromethorphan] in current cough and cold formulations.

    Mixtures: Vicodin ES, Vicodin ESCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 Substrates
  2. Drug

    Remdesivir

    go.drugbank.com/drugs/DB14761
    ApprovedInvestigational

    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia … Like other RNA viruses, SARS-CoV-2 depends on an RNA-dependent RNA polymerase (RdRp) enzyme complex for genomic replication, which can be inhibited by a class of drugs known as nucleoside analogues.

    Categories: MATE 1 Inhibitors, P-glycoprotein substratesProducts: VEKLURY® LYOPHILIZED POWDER FOR IV INFUSION 100MG/VIAL, VEKLURY 100 MG İNFÜZYONLUK ÇÖZELTİ KONSANTRESİ İÇİN TOZ, 1 ADET
  3. Drug

    Englumafusp alfa

    go.drugbank.com/drugs/DB19341
    Investigational

    and in Combination With Glofitamab Following a Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/refractory B-cell Non-hodgkin's Lymphoma). … Englumafusp alfa is under investigation in clinical trial NCT04077723 (A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab

    Synonyms: fusion protein with immunoglobulin G1 [497-ala, 71-248-4-1BB ligand (human precursor) fusion protein with peptide linker (GGGGS)2 fusion protein with 71-248-4-1BB ligand (human precursor) peptide linker (GGGGS)2 fusion protein with human κ-chain C region
  4. Drug

    Lorlatinib

    go.drugbank.com/drugs/DB12130
    ApprovedInvestigational

    Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer[L39905] which was first approved by the US FDA in November of 2018 … approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a

    Categories: MATE 1 Inhibitors, P-glycoprotein inducersProducts: LORBRENA® 25 MG, LORBRENA® 100 MG
  5. Drug

    Amisulpride

    go.drugbank.com/drugs/DB06288
    ApprovedInvestigational

    Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. … [A6752, L32764] Oral tablets of amisulpride is used in European countries as a treatment for acute and chronic schizophrenic disorders, as well as secondary negative symptoms in mental health disorders

    Categories: MATE 1 Inhibitors, MATE 1 SubstratesSynonyms: 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide, 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-O-anisamide
  6. Drug

    ALTU-135

    go.drugbank.com/drugs/DB05330
    Investigational

    ALTU-135 has been granted orphan drug and fast-track designation as well as CMA Pilot 2 program status by the Food and Drug Administration (FDA).

  7. Drug

    Fibrinolysin

    go.drugbank.com/drugs/DB05254
    Investigational

    The combination is available as ointment containing 1 BU (Biological Unit) Fibrinolysin and 666 BUs desoxyribonuclease per gram. … The light chain has a molecular weight of approximately 27,000 Da and contains the active center of Fibrinolysin; the heavy chain has a molecular weight of approximately 57,000 Da.

    Mixtures: FIBRASE SA
  8. Drug

    Latiglutenase

    go.drugbank.com/drugs/DB06326
    Investigational

  9. Drug

    Darolutamide

    go.drugbank.com/drugs/DB12941
    ApprovedInvestigational

    Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC).

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  10. Drug

    D-fluoromethyltyrosine F-18

    go.drugbank.com/drugs/DB15296
    Investigational

    D-fluoromethyltyrosine F-18 is under investigation in clinical trial NCT01089998 (PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Safety and Tolerability in Healthy Volunteers and Safety